TRIPTODUR CARE

Serial Number 99167826
641

Registration Progress

Application Filed
May 2, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Non-Final Action E-Mailed - 3-Month Extension Granted (XELG on 2025-12-29)
Due: Mar 26, 2026 59 days

Trademark Image

TRIPTODUR CARE

Basic Information

Serial Number
99167826
Filing Date
May 2, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
641
Status Date
Sep 26, 2025
Application
Pending
Classes
035 036 044

Rights Holder

Debiopharm International SA

99
Address
Chemin Messidor 5-7
Forum "après-demain"
Lausanne CH-1002
CH

Ownership History

Debiopharm International SA

Original Applicant
99
Lausanne CH

Legal Representation

Attorney
Stephen Pachol

USPTO Deadlines

Next Deadline
59 days remaining
Non-Final Action E-Mailed - 3-Month Extension Granted (XELG on 2025-12-29)
Due Date
March 26, 2026

Application History

9 events
Date Code Type Description Documents
Dec 29, 2025 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Dec 29, 2025 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Sep 26, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 26, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 26, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 22, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 11, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 2, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
May 2, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 035
providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance
Class 036
providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance
Class 044
providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance

Classification

International Classes
035 036 044